The Deal Register
Database › Equity financing › ZYUS Life Sciences Announces Filing of Amended and Restated LIFE…

Equity financing

ZYUS Life Sciences Announces Filing of Amended and Restated LIFE Offering Document

Lane
Equity financing
Announced
09 Feb 2026
Province
Saskatchewan
Industry
Healthcare & life sciences
Status
Announced
What the filing says
ZYUS Life Sciences Corporation (the " Company ") (TSXV: ZYUS ), a clinical‑stage life sciences company focused on the development and commercialization of novel non‑opioid drug candidates for pain management, is pleased to announce that it has filed an amended and restated offering document dated February 9, 2026 (the " Amended and Restated Offering Document ") with respect to the offering (the " LIFE Offering ") pursuant to and in accordance with the "listed issuer financing exemption" from the prospectus requirement available under section 5A.2 of National Instrument 45-106 - Prospectus…
Source

Compiled from public filings, court documents, exchange bulletins and issuer releases. Figures are as disclosed and are not independently verified.

Not financial, investment, legal or tax advice, and not an offer to buy or sell any security. Verify everything before you transact.

The Deal Register · Archive · Subscribe